GlassScriptPhysician profile
Keanan D Beierle
NPI 1316241730
$6,249.38
in general payments reported to CMS, 2019-2025
29 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $1,035 · 2023: $1,323 · 2024: $1,225 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.99 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $639.78 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $532.48 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472.76 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $462.10 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $343.06 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $320.79 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.78 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $296.97 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $252.72 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $229.04 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $126.28 | 2021-2025 | Austedo Xr |
| Alkermes, INC. | $125.14 | 2021-2025 | Aristada, Lybalvi |
| Vertical Pharmaceuticals, LLC | $119.03 | 2024-2025 | Relexxii |
| Tempus Ai, INC | $110.88 | 2024-2025 | Tempus Pixel, Tempus Pixel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $107.63 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $103.26 | 2022-2024 | Xelstrym, Secuado |
| Eisai INC. | $102.18 | 2021-2022 | |
| Almatica Pharma LLC | $93.35 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $82.80 | 2023 | Spravato, Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $77.65 | 2022-2023 | Quviviq |
| Indivior INC. | $77.45 | 2022-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $74.83 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $72.97 | 2025 | |
| Tris Pharma INC | $69.45 | 2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $68.75 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $25.11 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $19.28 | 2021 | |
| Neos Therapeutics, LP | $15.87 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keanan Beierle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.